Anyone reading Biogen’s press release on the flat failure of dexpramipexole in treating ALS couldn’t overlook the note of finality then R&D chief Doug Williams used to mark its grave 10 years ago. The drug failed the primary endpoint. Follow-up analysis left no doubt about the flop.
Williams recalls the readout in ALS as “a crushing blow.” And Biogen was done.
Dex, though, was not.